Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus

Autoimmunity Reviews

Volumn 12, Issue 7, 2013, Pages 694-702

  Sigges, Johanna ^a   Biazar, Cyrus ^a   Landmann, Aysche ^a,b   Ruland, Vincent ^a   Patsinakidis, Nikolaos ^a   Amler, Susanne ^a   Bonsmann, Gisela ^a   Kuhn, Annegret ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; ETRETIN; ETRETINATE; HYDROXYCHLOROQUINE; ISOTRETINOIN; MEPACRINE; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOID; RITUXIMAB; STEROID; SUNSCREEN; TACROLIMUS; THALIDOMIDE;

ACUTE SKIN LUPUS ERYTHEMATOSUS; AMERICAN COLLEGE OF RHEUMATOLOGY; CHRONIC SKIN LUPUS ERYTHEMATOSUS; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA AND SEVERITY INDEX; DIARRHEA; DRUG EFFICACY; EUROPE; EUROPEAN SOCIETY OF CUTANEOUS LUPUS ERYTHEMATOSUS CORE SET QUESTIONNAIRE; GASTROINTESTINAL SYMPTOM; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INTERMITTENT SKIN LUPUS ERYTHEMATOSUS; INTERMITTENT SKIN LUPUS EYTHEMATOSUS; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); NAUSEA; POLYNEUROPATHY; PROSPECTIVE STUDY; QUESTIONNAIRE; RETINOPATHY; REVIEW; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION; STATISTICAL ANALYSIS; SUBACUTE SKIN LUPUS ERYTHEMATOSUS; TERATOGENICITY; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING;

CROSS-SECTIONAL STUDIES; EUROPE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SOCIETIES, MEDICAL; SUNSCREENING AGENTS;

EID: 84877837895     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.10.005     Document Type: Review

References (65)

1. Tsokos G.C. Systemic lupus erythematosus. N Engl J Med 2011, 365:2110-2121.
2. Sciascia S., Bertolaccini M.L., Baldovino S., Roccatello D., Khamashta M.A., Sanna G. Central nervous system involvement in systemic lupus erythematosus: Overview on classification criteria. Autoimmun Rev 2013, 12:426-429.
3. Chan V.S., Nie Y.J., Shen N., Yan S., Mok M.Y., Lau C.S. Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus. Autoimmun Rev 2012, 11:890-897.
4. Gatto M., Zen M., Ghirardello A., Bettio S., Iaccarino L., Punzi L., et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 2013, 12:523-536.
5. Kuhn A., Ruzicka T. Classification of cutaneous lupus erythematosus. Cutaneous Lupus Erythematosus 2004, 53-58. Springer, Heidelberg. A. Kuhn, P. Lehmann, T. Ruzicka (Eds.).
6. Kuhn A., Ruland V., Bonsmann G. Photosensitivity, phototesting, and photoprotection in cutaneous lupus erythematosus. Lupus 2010, 19:1036-1046.
7. Kuhn A., Ruland V., Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options Part II. J Am Acad Dermatol 2011, 65:e195-e213.
8. Kuhn A., Ruland V., Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options Part I. J Am Acad Dermatol 2011, 65:e179-e193.
9. Kuhn A., Sárdy M. Topical glucocorticoids and calcineurin inhibitors in cutaneous lupus erythematosus. Am J Clin Dermatol 2011, [Epub.].
10. Wollina U., Hansel G. The use of topical calcineurin inhibitors in lupus erythematosus: an overview. J Eur Acad Dermatol Venereol 2008, 22:1-6.
11. Sardy M., Ruzicka T., Kuhn A. Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res 2009, 301:93-98.
12. Tzellos T.G., Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol 2008, 64:337-341.
13. Kuhn A., Ochsendorf F., Bonsmann G. Treatment of cutaneous lupus erythematosus. Lupus 2010, 19:1125-1136.
14. Ruzicka T., Meurer M., Bieber T. Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol 1988, 124:897-902.
15. Chang A.Y., Piette E.W., Foering K.P., Tenhave T.R., Okawa J., Werth V.P. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 2011, 147:1261-1267.
16. Jessop S., Whitelaw D.A., Delamere F.M. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009, CD002954.
17. Tzung T.Y., Liu Y.S., Chang H.W. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol 2007, 156:191-192.
18. Kuhn A., Gensch K., Haust M., Schneider S.W., Bonsmann G., Gaebelein-Wissing N., et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 2011, 65(54-64):e1-e2.
19. Jemec G.B., Ullman S., Goodfield M., Bygum A., Olesen A.B., Berth-Jones J., et al. A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus. Br J Dermatol 2009, 161:1365-1370.
20. Kuhn A., Kuehn E., Meuth A.M., Haust M., Nyberg F., Werth V., et al. Development of a core set questionnaire by the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 2009, 8:702-712.
21. Biazar C., Sigges J., Patsinakidis N., Ruland V., Amler S., Bonsmann G., et al. Cutaneous Lupus Erythematosus: First Multicenter Database Analysis of 1002 Patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 2013, 12:444-454.
22. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
23. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
24. Albrecht J., Taylor L., Berlin J.A., Dulay S., Ang G., Fakharzadeh S., et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005, 125:889-894.
25. Obermoser G., Zelger B. Triple need for photoprotection in lupus erythematosus. Lupus 2008, 17:525-527.
26. Vila L.M., Mayor A.M., Valentin A.H., Rodriguez S.I., Reyes M.L., Acosta E., et al. Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus. P R Health Sci J 1999, 18:89-94.
27. Kuhn A., Gensch K., Haust M., Meuth A.M., Boyer F., Dupuy P., et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol 2011, 64:37-48.
28. Kuhn A., Sonntag M., Richter-Hintz D., Oslislo C., Megahed M., Ruzicka T., et al. Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol 2001, 45:86-95.
29. Kuhn A., Sonntag M., Richter-Hintz D., Oslislo C., Megahed M., Ruzicka T., et al. Phototesting in lupus erythematosus tumidus-review of 60 patients. Photochem Photobiol 2001, 73:532-536.
30. Hampton P.J., Farr P.M., Diffey B.L., Lloyd J.J. Implication for photosensitive patients of ultraviolet A exposure in vehicles. Br J Dermatol 2004, 151:873-876.
31. Johnson J.A., Fusaro R.M. Broad-spectrum photoprotection: the roles of tinted auto windows, sunscreens and browning agents in the diagnosis and treatment of photosensitivity. Dermatology 1992, 185:237-241.
32. Roenigk H.H., Martin J.S., Eichorn P., Gilliam J.N. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis 1980, 25:281-285.
33. Kuhn A., Haust M., Bonsmann G. Klinik und Therapie von SLE Hautmanifestationen. Aktuelle Therapieoptionen beim systemischen Lupus erythematodes 2011, 56-63. Unimed Verlag, Bremen. 2nd edition. M. Aringer (Ed.).
34. Ruzicka T., Sommerburg C., Goerz G., Kind P., Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992, 127:513-518.
35. Wozniacka A., Carter A., McCauliffe D.P. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 2002, 11:71-81.
36. Ochsendorf F.R. Use of antimalarials in dermatology. J Dtsch Dermatol Ges 2010, 8:829-844.
37. Kalia S., Dutz J.P. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007, 20:160-174.
38. Walling H.W., Sontheimer R.D. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009, 10:365-381.
39. Ochsendorf F. Antimalarials. Cutaneous lupus erythematosus 2004, 347-372. Springer, Heidelberg. A. Kuhn, P. Lehmann, T. Ruzicka (Eds.).
40. Cuadrado M.J., Karim Y., Sanna G., Smith E., Khamashta M.A., Hughes G.R. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med 2005, 118:246-250.
41. Knop J., Bonsmann G., Happle R., Ludolph A., Matz D.R., Mifsud E.J., et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983, 108:461-466.
42. Tseng S., Pak G., Washenik K., Pomeranz M.K., Shupack J.L. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996, 35:969-979.
43. Bohm I., Bruns A., Schupp G., Bauer R. ANCA-positive lupus erythematodes profundus. Successful therapy with low dosage dapsone. Hautarzt 1998, 49:403-407.
44. McCormack L.S., Elgart M.L., Turner M.L. Annular subacute cutaneous lupus erythematosus responsive to dapsone. J Am Acad Dermatol 1984, 11:397-401.
45. Holtman J.H.N.D., Klein J., Callen J.P. Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency. J Rheumatol 1990, 17:1222-1225.
46. Fenton D.A., Black M.M. Low-dose dapsone in the treatment of subacute cutaneous lupus erythematosus. Clin Exp Dermatol 1986, 11:102-103.
47. Yamada Y., Dekio S., Jidoi J., Ozasa S. Lupus erythematosus profundus-report of a case treated with dapsone. J Dermatol 1989, 16:379-382.
48. Drake L.A., Dinehart S.M., Farmer E.R., Goltz R.W., Graham G.F., Hordinsky M.K., et al. Guidelines of care for cutaneous lupus erythematosus. American Academy of Dermatology. J Am Acad Dermatol 1996, 34:830-836.
49. Ruzicka T., Meurer M., Braun-Falco O. Treatment of cutaneous lupus erythematosus with etretinate. Acta Derm Venereol 1985, 65:324-329.
50. Kuhn A., Aberer E., Barde C., Foeldvari I., Haust M., Iking-Konert C Leitlinien Kutaner Lupus Erythematodes (Entwicklungsstufe 1). Dermatologische Qualitätssicherung: Leitlinien und Empfehlungen 2009, 214-257. ABW Wissenschaftsverlag GmbH, Berlin. H.C. Korting, R. Callies, M. Reusch, M. Schlaeger, W. Sterry (Eds.).
51. Bacman D., Kuhn A., Ruzicka T. Dapsone and retinoids. Cutaneous Lupus Erythematosus 2004, 373-390. Springer, Berlin. A. Kuhn, P. Lehmann, T. Ruzicka (Eds.).
52. Sadlier M., Kirby B., Lally A. Mycophenolate mofetil and hydroxychloroquine: an effective treatment for recalcitrant cutaneous lupus erythematosus. J Am Acad Dermatol 2012, 66:160-161. [author reply 1-2].
53. Gammon B., Hansen C., Costner M.I. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol 2011, 65:717-721.
54. Karim M.Y., Alba P., Cuadrado M.J., Abbs I.C., D'Cruz D.P., Khamashta M.A., et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002, 41:876-882.
55. Pisoni C.N., Karim Y., Cuadrado M.J. Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus 2005, 14(Suppl. 1):s9-s11.
56. Kreuter A., Tomi N.S., Weiner S.M., Huger M., Altmeyer P., Gambichler T. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol 2007, 156:1321-1327.
57. Kuhn A., Specker C., Ruzicka T., Lehmann P. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2002, 46:600-603.
58. Bohm L., Uerlich M., Bauer R. Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate. Dermatology 1997, 194:307-308.
59. Wenzel J., Brahler S., Bauer R., Bieber T., Tuting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 2005, 153:157-162.
60. Boehm I.B., Boehm G.A., Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int 1998, 18:59-62.
61. Bottomley W.W., Goodfield M.J. Methotrexate for the treatment of discoid lupus erythematosus. Br J Dermatol 1995, 133:655-656.
62. Goldstein E., Carey W. Discoid lupus erythematosus: successful treatment with oral methotrexate. Arch Dermatol 1994, 130:938-939.
63. Picco P., Gattorno M., Buoncompagni A., Vignola S., Pistoia V., Crovato F. A case of paediatric discoid lupus erythematosus evolving into SLE. Clin Exp Rheumatol 1998, 16:620.
64. Huber A., Tuting T., Bauer R., Bieber T., Wenzel J. Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration. Br J Dermatol 2006, 155:861-862.
65. Isenberg D.A. Rituximab-it was the best of times, it was the worst of times. Autoimmun Rev 2012, 11:790-791.